Core Viewpoint - The company plans to establish a subsidiary in Indonesia through its wholly-owned subsidiary WELL LEAD GLOBAL LIMITED, with a total investment of 500 billion Indonesian Rupiah (approximately 20 million RMB) to build a production base [2][4]. Group 1: Investment Overview - The investment will be made by WELL LEAD GLOBAL LIMITED contributing 475 billion Indonesian Rupiah for a 95% stake, while the chairman and actual controller, Xiang Bin, will invest 25 billion Indonesian Rupiah for a 5% stake [2][4]. - The investment aims to enhance the company's overseas production capabilities and expand its international market presence [4][15]. Group 2: Approval and Compliance - The investment has been approved by the company's board of directors with a unanimous vote, and the related party, Xiang Bin, abstained from voting [4][17]. - The investment is subject to necessary domestic and foreign investment filing procedures and local approvals in Indonesia [5][15]. Group 3: Financial and Operational Details - The total investment amount is 500 billion Indonesian Rupiah, which will be funded entirely from the company's own resources, ensuring no impact on its cash flow or financial stability [4][15]. - The investment will cover various aspects including leasing and renovating facilities, purchasing and installing equipment, and working capital [4][10]. Group 4: Related Party Transactions - The investment constitutes a related party transaction but does not qualify as a major asset restructuring under relevant regulations [2][6]. - The company has confirmed that there have been no other significant related party transactions exceeding 30 million RMB in the past 12 months [7][19]. Group 5: Future Implications - Establishing the Indonesian subsidiary is a strategic move to improve the company's global manufacturing footprint and meet international customer demands [15]. - The company anticipates that this investment will have a positive long-term impact on its growth and operational strategy [15].
证券代码:603309 证券简称:维力医疗 公告编号:2025-035